Findings

What do systematic reviews say?

873 questions · 883 findings · 38 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 319 · 36.1%GRADE not reported 18 · 2%Very low 198 · 22.4%Low 186 · 21.1%Moderate 147 · 16.6%High 15 · 1.7%

Summary of findings: repaglinide vs placebo

Hypoglycemia: number of episodes · adults with CFRD

It is very uncertain whether summary of findings: repaglinide changes hypoglycemia: number of episodes compared with placebo (very low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
RR 12.52 [0.74, 211.2]
1 study · 51 participants
Very low

Summary of findings: repaglinide vs insulin

HbA1c (glycated haemoglobin), change · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in hbA1c (%) change from baseline compared with insulin (high certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
MD 0.3
1 study · 67 participants
High

Summary of findings: repaglinide vs insulin

FEV1 (% predicted): mean change from baseline · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in FEV1 % predicted change from baseline compared with insulin (moderate certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 112 participants
Moderate

Summary of findings: repaglinide vs insulin

FVC (% predicted) Change from baseline · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in FVC % predicted change from baseline compared with insulin (moderate certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 112 participants
Moderate

Summary of findings: repaglinide vs insulin

Change in BMI · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in BMI (kg/m²) change from baseline compared with insulin (low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
MD 0.24
1 study · 45 participants
Low

Summary of findings: repaglinide vs insulin

Hypoglycemia: number of episodes · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in hypoglycemia number of episodes compared with insulin (low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
RR 1.38 [0.48, 4.01]
2 studies · 56 participants
Low

Summary of findings: NPH insulin vs insulin glargine

HbA1c (%) · adults with CFRD and fasting hyperglycemia

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: NPH insulin vs insulin glargine

FEV1 % predicted · adults with CFRD and fasting hyperglycemia

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: NPH insulin vs insulin glargine

FVC · adults with CFRD and fasting hyperglycemia

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: NPH insulin vs insulin glargine

Body‐mass index (BMI) · adults with CFRD and fasting hyperglycemia

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: NPH insulin vs insulin glargine

Hypoglycemia mean number of events per participant · adults with CFRD and fasting hyperglycemia

It is very uncertain whether summary of findings: NPH insulin changes hypoglycemia mean number of events per participant compared with glargine (very low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Very low

Summary of findings: repaglinide vs placebo

HbA1c (%) · adults with CFRD

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Very low

Summary of findings: repaglinide vs placebo

FEV1 (% predicted): mean change from baseline · adults with CFRD

Summary of findings: repaglinide showed no clear difference in FEV1 % predicted; change from baseline compared with placebo (low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
MD 1.7
1 study · 38 participants
Low

Summary of findings: repaglinide vs placebo

FVC (% predicted) Change from baseline · adults with CFRD

Summary of findings: repaglinide showed no clear difference in FVC % predicted: change from baseline compared with placebo (low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Low

Summary of findings: repaglinide vs placebo

Change in BMI · adults with CFRD

Summary of findings: repaglinide showed no clear difference in BMI (kg/m²): change from baseline compared with placebo (low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
MD 0.17
1 study · 38 participants
Low

Summary of findings: liprotamase vs porcine PERT

Change in weight (kg) · children aged 7 years or over and adults with cystic fibrosis

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 128 participants
Low

Summary of findings: liprotamase vs porcine PERT

Change in height · children aged 7 years or over and adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: liprotamase vs porcine PERT

Change in BMI · children aged 7 years or over and adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: liprotamase vs porcine PERT

Abdominal pain frequency or change in frequency · children aged 7 years or over and adults with cystic fibrosis

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 128 participants
Low

Summary of findings: liprotamase vs porcine PERT

CFA: change from baseline (%) · children aged 7 years or over and adults with cystic fibrosis

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 128 participants
Low